Author: sugaradmin

Introduction and Objective: Once-weekly (QW) insulin aims to reduce treatment burden by lowering injection frequency, potentially enhancing treatment acceptance and adherence. This trial evaluated the efficacy and safety of a novel QW insulin analog GZR4 versus once-daily (QD) insulin degludec (IDeg) in insulin-naïve subjects with T2D inadequately controlled by OADs.Methods: In this open-label, treat-to-target phase […]

Introduction and Objective: Our goal was to identify the value of continuous glucose monitor (CGM) screening to identify individuals with stage 2 type 1 diabetes (T1D). If these individuals are identified, then useful treatments, such as teplizumab, may help delay the onset of stage 3 (symptomatic) T1D.Methods: We used a group consensus process consisting of […]

Introduction and Objective: Glucagon-like peptide-1 receptor agonist (GLP-1RA) agents have demonstrated cardiovascular disease (CVD) benefits in adults with type 2 diabetes (T2D) at high and moderate CVD risk. However, their head-to-head comparative risk of cardiovascular outcomes is unknown.Methods: We conducted a clinical trial emulation comparing CVD outcomes between patients treated with four GLP-1RAs. Using medical […]

Introduction and Objective: Acyl-CoA synthetase long-chain family member 1 (ACSL1) is activated in macrophages by palmitate, driving foam cell formation through the CD36/FABP4/PPARδ axis. Our prior research showed that inhibiting ACSL1 reduces inflammation and alters lipid uptake, suggesting it as a therapeutic target. Here, we examined whether oral Triacsin C, a small-molecule ACSL inhibitor, can […]

Introduction and Objective: Pemvidutide is a long-acting, peptide-based GLP-1/glucagon dual receptor agonist that elicits significant reductions in body weight and serum lipids in preclinical and clinical studies. Reverse cholesterol transport (RCT) is an important process for removing excess cholesterol from peripheral tissues. Preclinical studies have suggested that glucagon may enhance the elimination of cholesterol, possibly […]

Introduction and Objective: We have discovered that verapamil inhibits pancreatic islet expression of beta cell toxic thioredoxin-interacting protein (TXNIP) and preserves beta cell function in mice and in subjects with T1D and these clinical findings have been independently validated. However, as a calcium channel blocker, verapamil has many additional effects. We therefore aimed to explore […]

Introduction and Objective: This study aimed to explore the mechanism of the dual GCGR/GLP-1R agonist mazdutide for improving liver fat accumulation compared to the GLP-1R agonist semaglutide.Methods: Mazdutide (30 nmol/kg per week) or semaglutide (30 nmol/kg every other day) was administrated subcutaneously for 8 weeks in diet-induced obesity mice to maintain a comparable level of […]

Introduction and Objective: Young adults with type 1 diabetes (T1D) have higher glycemia than other age groups, yet in this time of childbearing potential there are limited data on how the transition to adult care impacts gestational outcomes.Methods: Retrospective chart review at the Barbara Davis Center for Diabetes between 2014 and 2020 of women with […]

Introduction and Objective: Mazdutide (IBI362) is a dual agonist of GLP-1R and GCGR. Previous studies indicated that it significantly reduces serum uric acid levels in hyperuricemic rats compared to semaglutide. This study aims to further clarify the mechanism by which Mazdutide lowers uric acid in these rats.Methods: A hyperuricemia model was established in SD rats […]

Introduction and Objective: The use of electronic health records (EHR) to identify incident conditions in observational studies is growing. Health care encounters are related to health status and possibly other unobserved characteristics, which can lead to a phenomenon termed “encounter bias”. Several prior studies discussed potential encounter bias between encounter types and outcomes such as […]